The authors describe the design as a high-dose toxicology model, not a representation of typical human dietary exposure. DBDPE exposure was associated with changes in measured organ indices, serum biochemical markers and descriptive liver and kidney morphology. The liver index was 5.06% ± 0.20% in controls and 5.89% ± 0.60% in DBDPE-exposed mice; the kidney index was 1.02% ± 0.10% and 1.16% ± 0.07%, respectively.

Compared with controls, the DBDPE group had higher serum gamma-glutamyltransferase, alkaline phosphatase, creatinine, uric acid, lactate dehydrogenase and total cholesterol values, alongside lower albumin and triglyceride values. Representative liver sections showed hepatocyte vacuolization, cell aggregates, altered tissue arrangement and areas with a necrosis-like appearance, while Oil Red O staining showed more prominent lipid droplets in the DBDPE group. Representative kidney sections showed tubular epithelial degeneration and desquamation, periglomerular cell aggregation, vasodilation and congestion.

Because no histopathological scoring or morphometry was applied, these images describe morphology without quantifying lesion severity or establishing functional organ damage. Its liver index was 5.17% ± 0.41% and its kidney index was 1.06% ± 0.03%, both lower than in the DBDPE-only group. The liver-index mean difference was −0.72 percentage points, with a two-sided 97.5% confidence interval of −1.32 to −0.12 and a Bonferroni-adjusted p value of 0.018.

The kidney-index difference was −0.10 percentage points, with a confidence interval of −0.16 to −0.04 and an adjusted p value of 0.002. The multiplicity adjustment covered these two primary outcomes. In the wider serum panel, gamma-glutamyltransferase, creatinine and uric acid were lower and triglycerides and albumin were higher in one or more resveratrol pretreatment groups than in DBDPE-only animals, although responses varied among endpoints and doses.

Redox-related measurements also differed after DBDPE exposure. Serum malondialdehyde, a readout compatible with increased lipid peroxidation, rose from 8.05 to 10.61 nmol/mL, while total nitric oxide synthase activity increased from 12.23 to 14.81 U/mL. Serum glutathione S-transferase, glutathione peroxidase and superoxide dismutase activities fell from 20.53 to 18.50 U/mL, 428.19 to 368.99 U/mL and 272.02 to 185.50 U/mL, respectively.

In liver tissue, malondialdehyde increased from 2.00 to 7.91 nmol/mg, while glutathione peroxidase, catalase, reduced glutathione and superoxide dismutase values were lower than in controls. The kidney followed a similar measured pattern: malondialdehyde rose from 2.26 to 4.44 nmol/mg, with lower glutathione peroxidase, catalase, glutathione and superoxide dismutase values. Dihydroethidium-derived liver fluorescence was also higher in the DBDPE group.

This fluorescence is an indirect, semiquantitative redox-associated measure rather than a species-specific measurement of reactive oxygen species or superoxide. Several resveratrol groups had values closer to the control pattern in these redox endpoints. Hepatic malondialdehyde was 3.98 nmol/mg in the medium-dose pretreatment group.

In the high-dose group, hepatic glutathione peroxidase, catalase, glutathione and superoxide dismutase were 60.11 U/mg, 853.90 U/g, 1.55 μmol/g and 327.48 U/mg, compared with 37.26 U/mg, 721.83 U/g, 1.07 μmol/g and 236.55 U/mg in the DBDPE-only group. Renal malondialdehyde was lower in all three pretreatment groups, at 3.81, 3.06 and 3.98 nmol/mg for the 25, 50 and 100 mg/kg groups. Glutathione peroxidase and glutathione were higher in the medium- and high-dose groups, while high-dose catalase activity was 115.99 U/g.

Dihydroethidium fluorescence was also lower in the resveratrol groups. These are group associations; the experiment did not show that resveratrol directly scavenged reactive molecules or that any redox change mediated the organ-index or morphological differences. RT-qPCR measurements identified further differences in selected antioxidant-related transcripts.

The researchers quantified Pik3r1, Nfe2l2, Sod2, Cat and Gpx1 in liver and kidney tissue, using three biological samples per group. DBDPE exposure was associated with lower expression of these selected transcripts than in controls. In liver, Sod2 and Cat expression fell from 1.00 ± 0.08 and 1.00 ± 0.22 in controls to 0.29 ± 0.04 and 0.24 ± 0.06 after DBDPE exposure, while the medium-dose resveratrol group measured 11.11 ± 0.38 and 9.58 ± 0.19.

In kidney, Nfe2l2 and Cat expression declined from 1.00 ± 0.03 and 1.00 ± 0.10 to 0.47 ± 0.01 and 0.33 ± 0.07 after DBDPE alone; the high-dose resveratrol group measured 3.55 ± 0.09 and 1.90 ± 0.56. These transcript measurements do not demonstrate PI3K activity, Nrf2 protein abundance or nuclear translocation, and the response was not monotonic across the three resveratrol doses. DBDPE exposure was also accompanied by higher assay-accessible iron readouts in serum, liver and kidney.

The commercial assay output was labelled Fe2+, but its selectivity for the ferrous iron pool over total assay-accessible iron was not established, so the results are interpreted as assay-accessible iron rather than a specific measurement of that pool. Serum values increased from 57.41 ± 0.79 to 91.76 ± 1.37 μmol/L, liver readings from 2.01 ± 0.03 to 3.44 ± 0.02 μmol/g protein, and kidney readings from 2.33 ± 0.05 to 4.61 ± 0.04 μmol/g protein. Values were lower in the resveratrol pretreatment groups than in the DBDPE-only group across all three sample types.

Western blots showed lower GPX4 and higher TFR1 abundance in DBDPE-exposed liver, with higher GPX4 in the high-dose resveratrol group and lower TFR1 in the low- and medium-dose groups. The kidney protein pattern was less consistent, and hepatic ACSL4 did not show the canonical increase associated with the DBDPE group. Changes in ferroptosis-associated transcripts accompanied these measurements but did not establish ferroptotic cell death.

In DBDPE-exposed liver, Tfrc expression increased from 1.01 ± 0.12 to 2.15 ± 0.02 and Acsl4 rose from 1.00 ± 0.02 to 1.54 ± 0.04, while Slc7a11 fell from 1.00 ± 0.07 to 0.12 ± 0.01 and Gpx4 declined from 1.01 ± 0.13 to 0.45 ± 0.06. In the high-dose resveratrol group, Tfrc and Acsl4 measured 0.88 ± 0.06 and 0.96 ± 0.14. In kidney, DBDPE-associated Tfrc and Acsl4 expression was higher than in controls, whereas the high-dose resveratrol group had Slc7a11 and Gpx4 expression of 3.30 ± 0.18 and 5.09 ± 0.05 and Acsl4 expression of 1.04 ± 0.01.

Representative transmission electron micrographs from DBDPE-exposed tissues showed irregular or shrunken mitochondria, blurred or discontinuous membranes, fragmented cristae and increased matrix electron density; some pretreatment fields appeared more regular. No ferroptosis-specific inhibitor, genetic perturbation, rescue experiment or quantitative ultrastructural analysis was performed. Several limitations restrict how far the results can be interpreted.

Only female Kunming mice were studied, estrous-cycle stage was not monitored or controlled, and no prospective power calculation was performed. Several terminal assays used three randomly selected animals from each nine-animal group, limiting sensitivity and making those findings exploratory. Cage was not included as a random or fixed effect in the analysis, so possible dependence among cage mates was not fully accounted for.

Histology and mitochondrial observations relied on representative fields without quantitative scoring. The delivered DBDPE concentration, homogeneity and stability were not analytically verified, and resveratrol storage stability was not separately assessed. The apparent non-monotonic response across 25, 50 and 100 mg/kg cannot establish hormesis, a formal dose-response relationship or an optimal dose because no prespecified trend analysis, dose-response model or pharmacokinetic assessment was performed.

Resveratrol alone also changed several transcripts, including lower hepatic Slc7a11, showing that its effects were marker- and tissue-dependent. The findings support a narrower conclusion than a demonstration of protection against human disease. Under this high-dose, 28-day mouse model, DBDPE exposure was accompanied by selected serum biochemical changes, descriptive liver and kidney morphology, redox differences, higher assay-accessible iron values, mitochondrial changes and tissue-dependent ferroptosis-associated markers.

Resveratrol pretreatment accompanied lower values across several of those endpoints, with the clearest primary results involving the two relative organ indices. The experiment does not establish ferroptosis, inhibition of ferroptosis, activation of PI3K/Nrf2 signaling or a causal sequence from oxidative stress to tissue changes. It also cannot define a DBDPE dose-response relationship, a no-observed-adverse-effect level or a dietary risk estimate.

The purified resveratrol doses were experimental gavage regimens and are not proposed as achievable through ordinary intake of resveratrol-containing foods, so the results do not support a dietary recommendation or direct extrapolation to typical human exposure.

Subject of Research: Resveratrol pretreatment and DBDPE-associated liver, kidney, redox and ferroptosis-associated markers in female mice

Article Title: Resveratrol Pretreatment and Decabromodiphenyl Ethane‐Associated Hepatorenal Changes in a High‐Dose Female Mouse Model: Redox Changes and Ferroptosis‐Associated Markers

Article References: Ji, Y., Liu, C., Wu, X., Shi, M., Hu, T., He, J., Wei, Y., Wang, L., & Yu, M. (2026). Resveratrol Pretreatment and Decabromodiphenyl Ethane‐Associated Hepatorenal Changes in a High‐Dose Female Mouse Model: Redox Changes and Ferroptosis‐Associated Markers. Food Science & Nutrition, 14(10), Article e72495. https://doi.org/10.1002/fsn3.72495

Image Credits: AI Generated

DOI: 10.1002/fsn3.72495

Keywords: DBDPE, resveratrol, female mice, hepatotoxicity, renal toxicity, oxidative stress, iron homeostasis, ferroptosis markers, brominated flame retardants, food safety, Pretreatment, Decabromodiphenyl

TRPM2, short for transient receptor potential melastatin 2, occupies a unique position at the intersection of calcium signaling and redox biology. Unlike most ion channels, TRPM2 is gated not only by changes in the cellular redox state but also by adenosine diphosphate ribose (ADPR), a second messenger produced during oxidative stress. When reactive oxygen species accumulate, ADPR is generated and binds to the channel’s Nudix box motif, opening a floodgate for extracellular calcium. This influx can push cells toward mitochondrial dysfunction, caspase activation, and ultimately apoptosis. Because TRPM2 activation is tightly coupled to oxidant generation, the channel has become a prime target for compounds that might interrupt this deadly feedback loop.

The research team, led by Aysun Alparslan Çulha and Abdülhadi Cihangir Uğuz, designed a six-group experiment to dissect these interactions. CHO-K1 cells were assigned to control, resveratrol alone, hydrogen peroxide (H₂O₂) alone, ADPR alone, H₂O₂ plus resveratrol, and ADPR plus resveratrol conditions. This design allowed the investigators to compare the effects of each stimulus individually and to determine whether resveratrol pretreatment could modify the injury patterns. H₂O₂ served as a direct oxidant challenge, while ADPR acted as the specific intracellular gate opener for TRPM2, enabling the researchers to separate oxidant-driven from channel-driven components of the cellular response.

The results were striking. Both H₂O₂ and ADPR significantly increased the integrated intracellular calcium response, a readout that captures the total calcium load entering the cells over the measurement period. Calcium dysregulation of this kind is a well-established trigger for mitochondrial permeability transition and apoptotic signaling. The two stimuli also elevated apoptosis markers, increased JC-1 fluorescence indicating mitochondrial membrane depolarization, and boosted caspase-3 and caspase-9 activities, the executioner and initiator enzymes of the intrinsic apoptotic pathway. In parallel, intracellular oxidant production rose, and malondialdehyde (MDA), a lipid peroxidation product, increased as evidence of membrane damage.

Resveratrol pretreatment attenuated most of these stimulus-associated changes. The polyphenol reduced the integrated calcium response, dampened caspase activities, lowered apoptosis-related endpoints, and decreased intracellular oxidant generation as measured by the dihydrorhodamine-123 assay. It also restored the cellular antioxidant defenses: reduced glutathione (GSH) levels and glutathione peroxidase (GSH-Px) activity, which had been depleted by H₂O₂ and ADPR, were brought back toward control values. GSH is the cell’s most abundant nonprotein thiol antioxidant, and GSH-Px is the selenium-dependent enzyme that uses it to neutralize peroxides, so their recovery indicates that resveratrol strengthened the enzymatic and nonenzymatic arms of the antioxidant system.

One result stood out as an apparent exception. Resveratrol did not decrease the MDA response under the tested conditions, even though it reduced the oxidant readout from the dihydrorhodamine-123 assay. The authors address this dissociation directly, noting that the two assays operate on different temporal and analytical resolutions. Dihydorhodamine-123 fluorescence captures a relatively rapid window of intracellular oxidant generation, while MDA reflects cumulative lipid peroxidation that may have already progressed by the time of measurement. In other words, the two readouts are not simply redundant measures of the same phenomenon; they sample different moments and molecular targets of the oxidative injury process, and the mismatch does not necessarily contradict the protective pattern seen elsewhere.

The mechanistic significance of these findings extends beyond the laboratory dish. TRPM2 has been implicated in a wide range of pathologies, including ischemia-reperfusion injury, neurodegenerative disease, inflammation, and diabetic complications. Previous work from the same research community has shown that resveratrol modulates TRPM2 activity in models of hypoxia-induced neuronal death, bisphenol A-induced kidney injury, and MPP⁺-induced neurotoxicity. The present study adds a controlled, transfected-cell model in which the channel’s role can be isolated from the complexity of primary tissue, providing a clean platform for testing how resveratrol interacts with the channel at the molecular level.

The authors are careful to frame their conclusions within the limits of the model. They note that the findings support further mechanistic research but that TRPM2-specific causality and any reproductive relevance require confirmation in appropriate controls and primary cells. CHO-K1 cells are a well-established expression system, but they are not primary ovarian cells, and the transient transfection approach means that channel expression levels may vary between experiments. The study also used a single resveratrol concentration and a defined pretreatment window, leaving open questions about dose-response relationships and the timing of protection that would need to be addressed in follow-up work.

What makes this study compelling for a broader audience is the way it connects a familiar dietary compound to a precise molecular target. Resveratrol has been the subject of hundreds of investigations, with proposed roles in cancer prevention, cardiovascular protection, and healthy aging, but its mechanisms have often remained diffuse. By showing that resveratrol modifies calcium-associated, mitochondrial, and apoptotic responses in cells expressing a specific oxidant-gated channel, the research provides a concrete molecular handle on how the polyphenol may exert its protective effects. The work also reinforces the growing recognition that ion channels like TRPM2 are not merely passive conduits but active participants in the oxidative stress response, and that targeting them pharmacologically may offer a route to interrupting cell death pathways at their source.

As research into TRPM2 and oxidative calcium signaling continues to advance, studies like this one serve as building blocks for a more complete picture of how cells sense and respond to redox danger. The demonstration that resveratrol can attenuate calcium dysregulation, preserve antioxidant defenses, and reduce apoptotic signaling in a controlled expression model offers a template for future investigations into dietary polyphenols as modulators of ion channel function. Whether these findings will translate into clinical applications remains an open question, but the mechanistic clarity achieved here marks a meaningful step forward in understanding how a red grape compound may protect cells from the destructive coupling of oxidative stress and calcium overload.

Subject of Research: Cell Biology

Article Title: Resveratrol attenuates hydrogen peroxide- and ADP-ribose-associated calcium dysregulation, oxidative stress, and apoptosis in TRPM2-transfected Chinese hamster ovary (CHO)-K1 cells

Article References: Alparslan Çulha, A., Tola, E. N., Köse, S. A., & Uğuz, A. C. (2026). Resveratrol attenuates hydrogen peroxide- and ADP-ribose-associated calcium dysregulation, oxidative stress, and apoptosis in TRPM2-transfected Chinese hamster ovary (CHO)-K1 cells. Molecular Biology Reports, 53(1), Article 1748. https://doi.org/10.1007/s11033-026-12903-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12903-7

Keywords: resveratrol, TRPM2, calcium signaling, oxidative stress, apoptosis, ADP-ribose, CHO-K1 cells, antioxidant, attenuates, hydrogen, peroxide-, ADP-ribose-associated

The study, published in the Journal of Materials Science, focused on J774.2 mammalian macrophages, a widely used cell line for studying immune responses. Macrophages are the sentinels of the immune system, capable of both igniting and calming inflammation. When conventional chemotherapy with doxorubicin is administered, macrophages often respond by secreting excessive amounts of pro-inflammatory cytokines, small signaling proteins that can amplify tissue damage and contribute to the systemic toxicity that limits doxorubicin’s clinical use. Resveratrol, found naturally in grapes and berries, has long been recognized for its potent anti-inflammatory properties, but in its free form it suffers from poor water solubility and low bioavailability, rendering it largely ineffective when administered alone.

To overcome these limitations, the researchers engineered doubly loaded nanogels (DR-NG) and polymeric micelles (DR-M), each carrying both doxorubicin and resveratrol. These nanoscale carriers protect resveratrol from degradation, improve its solubility, and deliver both drugs directly to macrophages in a controlled manner. The team treated macrophages with standardized doses of 1, 5, and 10 micrograms per milliliter of both the pure drugs and the nanoformulations, under both basal conditions and in an inflammatory environment induced by lipopolysaccharide (LPS), a molecule that mimics bacterial infection and triggers a robust immune response.

The results were striking. All treatment groups maintained high cellular integrity, with over 90 percent cell viability as measured by the MTT assay, confirming that the nanosystems were not inherently toxic to the macrophages. But the immunological effects told a far more compelling story. Pure doxorubicin, when administered alone, exacerbated the inflammatory environment, approximately doubling the secretion of tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine. Pure resveratrol, on the other hand, was immunologically ineffective at the tested doses, likely due to its poor solubility and limited cellular uptake in free form.

In sharp contrast, the dual-loaded nanoformulations showed significant and statistically meaningful inhibition of interleukin-6 (IL-6) and interleukin-12p40 (IL-12p40), both critical mediators of inflammation, with P values below 0.001. Even more remarkably, the polymeric micelles (DR-M) successfully neutralized the doxorubicin-induced increase in TNF-α, reducing its levels below those of the control group containing only LPS. This suggests that the nanoencapsulation of resveratrol alongside doxorubicin transforms an otherwise inactive free drug into a potent immunomodulator capable of counteracting the pro-inflammatory side effects of chemotherapy.

Granulocyte-macrophage colony-stimulating factor (GM-CSF), another cytokine measured in the study, remained largely unaffected across all treatment groups. This selectivity is significant: it indicates that the dual-loaded nanosystems do not broadly suppress immune function but instead target hyper-inflammatory cascades specifically. Preserving systemic immune capacity while preventing uncontrolled cytokine release is precisely the balance that nanomedicine strives to achieve, and these results suggest the researchers have struck it.

The implications for cancer therapy are profound. Doxorubicin is a cornerstone of chemotherapy for breast cancer, lymphoma, and sarcoma, among others, but its use is often limited by cardiotoxicity, neurotoxicity, and the induction of systemic inflammation. Previous studies have explored resveratrol’s chemoprotective effects against doxorubicin-induced cardiotoxicity, but the poor bioavailability of free resveratrol has hampered clinical translation. By co-delivering both drugs in a single nanoscale vehicle, the researchers have not only improved resveratrol’s solubility and stability but also created a synergistic therapeutic partnership that enhances the overall therapeutic index of chemotherapy.

The choice of nanocarrier matters as well. Nanogels, three-dimensional hydrogel networks at the nanoscale, offer high drug loading capacity and controlled release kinetics. Polymeric micelles, self-assembled structures with a hydrophobic core and hydrophilic shell, excel at solubilizing hydrophobic drugs and prolonging circulation time. The fact that both carriers produced similar immunomodulatory outcomes, with the micelles showing a particularly strong capacity to neutralize TNF-α, suggests that the dual-loading strategy itself, rather than the specific carrier architecture, is the key driver of the synergistic effect.

This study adds to a growing body of evidence that nanotechnology can fundamentally reshape how we deploy conventional chemotherapy. Rather than simply wrapping a single drug in a nanoscale package, researchers are now designing multifunctional nanosystems that combine cytotoxic agents with immunomodulatory compounds, creating therapies that kill tumors while simultaneously protecting healthy tissue from collateral inflammatory damage. The doubly loaded nanogels and micelles developed here represent a promising step in that direction, offering a strategy to prevent uncontrolled cytokine release and preserve immune capacity during cancer treatment.

As the field of cancer nanotechnology matures, the ability to fine-tune the immune environment alongside tumor cell killing will become increasingly central to therapeutic design. The work presented here demonstrates that nanoencapsulation can transform a poorly bioavailable natural compound into a powerful ally for conventional chemotherapy, opening new avenues for enhancing the safety and efficacy of some of the most widely used anticancer drugs in clinical practice today.

Subject of Research: Dual-loaded nanogels and micelles for the synergistic immunomodulation of doxorubicin and resveratrol in J774.2 macrophages

Article Title: Dual-loaded nanogels and micelles for the synergistic immunomodulation of doxorubicin and resveratrol in J774.2 macrophages

Article References: Atalay, B. R., Radeva, L., Yoncheva, K., Aydemir, E., & Ayaz, F. (2026). Dual-loaded nanogels and micelles for the synergistic immunomodulation of doxorubicin and resveratrol in J774.2 macrophages. Journal of Materials Science. https://doi.org/10.1007/s10853-026-13684-x

Image Credits: AI Generated

DOI: 10.1007/s10853-026-13684-x

Keywords: nanomedicine, immunomodulation, doxorubicin, resveratrol, macrophages, drug delivery, cancer therapy, nanogels, polymeric micelles, cytokines, Dual-loaded, micelles

To appreciate the significance of the experimental design, it helps to understand why the inducible liver-specific insulin receptor knockout (iLIRKO) mouse model is so informative. Unlike global insulin receptor knockouts, which are embryonically lethal or produce overwhelming systemic dysfunction, liver-specific models allow researchers to isolate the contribution of hepatic insulin signaling to whole-body metabolism. The inducible nature of the model is equally important: it permits deletion of the insulin receptor in adult animals, after normal development has occurred, thereby avoiding developmental compensation that could confound interpretation. When insulin signaling is lost specifically in hepatocytes, the liver behaves as if it is in a fasting state regardless of nutritional status, driving unregulated gluconeogenesis, glycogenolysis, and very-low-density lipoprotein production. The resulting hyperinsulinemia is a compensatory response by pancreatic beta cells, which expand in mass and secretory capacity to overcome peripheral resistance.

The mTORC1 pathway sits at the center of this compensatory response. Mechanistic target of rapamycin complex 1 is a nutrient- and growth-factor-sensitive kinase complex that integrates signals from insulin, amino acids, energy status, and stress to regulate protein synthesis, lipid synthesis, autophagy, and cell growth. In pancreatic beta cells, mTORC1 activation is a well-established driver of compensatory proliferation and hypertrophy. While this expansion initially helps to maintain glucose homeostasis, chronic mTORC1 hyperactivation can eventually lead to beta cell exhaustion, ER stress, and apoptosis, contributing to the transition from compensated insulin resistance to overt type 2 diabetes. The finding that beta cell expansion in iLIRKO mice proceeds in an mTORC1-dependent manner therefore identifies a specific molecular node at which therapeutic intervention might preserve compensatory capacity while preventing its eventual collapse.

Resveratrol, a stilbenoid polyphenol found in grapes, red wine, berries, and peanuts, has been the subject of intense investigation since the early 2000s, when it was first reported to activate sirtuin pathways and extend lifespan in yeast. Subsequent research revealed that resveratrol engages multiple molecular targets, including AMP-activated protein kinase (AMPK), silent information regulator 1 (SIRT1), nuclear factor erythroid 2-related factor 2 (Nrf2), and, critically for this study, the tuberous sclerosis complex 2 (TSC2). TSC2 functions as a GTPase-activating protein that suppresses Rheb, the direct activator of mTORC1. When TSC2 is phosphorylated or acetylated at specific residues, its ability to inhibit mTORC1 is modulated. The authors’ prior work demonstrated that resveratrol modulates the acetylation status of TSC2, thereby enhancing its suppressive effect on mTORC1 signaling. This mechanism provides a direct molecular explanation for how resveratrol could dampen the excessive mTORC1 activity that drives pathological beta cell expansion and hepatic lipogenesis.

The extension of insulin resistance from the liver to adipose tissue deserves particular attention. In the iLIRKO model, the researchers observed that white adipose tissue and brown adipose tissue both developed secondary insulin resistance, characterized by increased lipolysis, reduced lipid accumulation, and smaller adipocyte size. This phenomenon, sometimes referred to as “lipotoxic spillover,” occurs because the liver, unable to properly store or metabolize incoming nutrients, exports excess lipids into the circulation as triglyceride-rich lipoproteins. These circulating lipids are taken up by adipose tissue, which becomes progressively insulin resistant as it attempts to cope with the lipid burden. When adipose tissue insulin resistance develops, the normal suppression of hormone-sensitive lipase and adipose triglyceride lipase is lost, leading to uncontrolled free fatty acid release into the portal and systemic circulation. These fatty acids further burden the liver, completing a vicious cycle of lipid dysregulation.

The consequence of this cycle for the liver is hepatic steatosis, the accumulation of triglycerides within hepatocytes. Non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately one-quarter of the global adult population and represents the hepatic manifestation of metabolic syndrome. In its early stages, hepatic steatosis is reversible, but progressive inflammation, hepatocyte ballooning, and fibrosis can lead to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The fact that resveratrol treatment reduced hepatic lipid accumulation in the iLIRKO model suggests that it may interrupt this progression at a critical upstream point, before irreversible damage occurs.

When the researchers fed iLIRKO mice a high-fat diet, the metabolic deterioration was substantially aggravated. This is consistent with the well-established concept of the “double hit” or “multiple-hit” hypothesis in NAFLD pathogenesis, whereby genetic or hormonal predisposition (in this case, hepatic insulin resistance) combines with dietary lipid excess to accelerate disease progression. The high-fat diet provides an abundance of fatty acids that overwhelm already compromised hepatic oxidative capacity, leading to more pronounced steatosis, greater oxidative stress, and enhanced inflammatory signaling. That resveratrol was able to ameliorate these aggravated alterations suggests that its mechanism of action is robust enough to counteract even compounded metabolic stress.

From a translational perspective, the dose, bioavailability, and safety profile of resveratrol are important considerations. Resveratrol exhibits relatively low oral bioavailability due to rapid hepatic glucuronidation and sulfation, and plasma concentrations achieved with typical dietary supplementation are often far below those used in cell culture experiments. However, some studies have demonstrated that even modest oral doses can produce measurable metabolic effects in rodents and humans, possibly because active metabolites or tissue-specific accumulation contribute to the overall biological response. Clinical trials of resveratrol in patients with type 2 diabetes, metabolic syndrome, and NAFLD have produced mixed but generally encouraging results, with improvements in insulin sensitivity, glycemic control, and liver enzymes reported in several randomized controlled trials, though the magnitude of benefit varies considerably across studies.

The mTORC1 pathway is also the target of several established and investigational pharmacological agents. Rapamycin and its analogs (rapalogs) directly inhibit mTORC1 and are used clinically as immunosuppressants and anticancer agents. Metformin, the first-line pharmacological treatment for type 2 diabetes, indirectly suppresses mTORC1 through AMPK activation. Glucagon-like peptide-1 (GLP-1) receptor agonists, which have revolutionized the treatment of obesity and type 2 diabetes, also modulate mTORC1 signaling in certain tissues. The fact that resveratrol achieves mTORC1 downregulation through a distinct mechanism, namely TSC2 acetylation modulation, suggests that it could potentially be combined with these other agents to achieve additive or synergistic effects, though this hypothesis would require dedicated experimental testing.

The open-access nature of this publication, published under a Creative Commons Attribution 4.0 license, facilitates the dissemination of these findings to researchers, clinicians, and the broader public. The availability of supplementary figures and original blot images further supports transparency and reproducibility, allowing independent researchers to verify the reported results and build upon them. The work was supported by Spanish national and regional funding agencies, including the Ministry of Science and Innovation (MICIN), the State Research Agency (AEI), the European Regional Development Fund (FEDER), and the Comunidad de Madrid, reflecting the multi-level investment in metabolic disease research in Spain.

Looking forward, several questions remain to be addressed. First, the long-term safety and efficacy of resveratrol in the context of chronic metabolic disease requires further investigation, particularly given that mTORC1 inhibition can have pleiotropic effects on immune function, wound healing, and aging. Second, the specific molecular interactions between resveratrol and TSC2 acetyltransferases or deacetylases need to be more precisely characterized to enable the development of targeted therapeutics that mimic this effect without the off-target activities of a promiscuous polyphenol. Third, the translational gap between mouse models and human disease remains substantial, and well-designed clinical trials with appropriate endpoints, adequate sample sizes, and sufficient duration will be essential to determine whether the promising preclinical results reported here can be replicated in human patients with diabesity and associated hepatic complications.

The study also highlights the value of using genetically defined animal models to dissect the contribution of individual tissues to systemic metabolic disease. By isolating the liver as the primary site of insulin resistance, the researchers were able to trace the cascade of secondary effects that propagate to adipose tissue, pancreas, and back to the liver itself. This systems-level understanding of how metabolic dysfunction propagates across organs is essential for developing interventions that address the root causes rather than merely the symptoms of diabesity. The identification of mTORC1 as a convergent node in this cascade provides a clear mechanistic target for future drug development efforts aimed at breaking the self-reinforcing cycle of insulin resistance, compensatory hyperinsulinemia, and ectopic lipid accumulation that underlies one of the most prevalent chronic disease clusters of the modern era.

Subject of Research: Resveratrol ameliorates diabesity-associated insulin resistance and hepatic steatosis via mTORC1 downregulation

Article Title: Resveratrol ameliorates diabesity-associated insulin resistance and hepatic steatosis via mTORC1 downregulation

Article References: Marqués, P., González-Blanco, C., García, G., Jiménez, B., García-Aguilar, A., Rada, P., Valverde, Á. M., Fernández-Millán, E., Vázquez, P., Iglesias-Fortes, S., Palomino, O., Benito, M., & Guillén, C. (2026). Resveratrol ameliorates diabesity-associated insulin resistance and hepatic steatosis via mTORC1 downregulation. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03343-0

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03343-0

Keywords: Resveratrol, ameliorates, diabesity-associated, insulin, resistance, hepatic, steatosis, mTORC1, downregulation, scientific research

The starting point of the review is the pathogenesis of atherosclerosis itself. The disease begins when the endothelium, the single layer of cells lining the arterial wall, becomes dysfunctional under the combined assault of high blood pressure, disturbed blood flow, smoking, diabetes and oxidized lipids. Damaged endothelial cells express adhesion molecules such as ICAM-1 and VCAM-1, which allow circulating monocytes to stick to the vessel wall and squeeze between them into the intima. There, the monocytes mature into macrophages that engulf modified low-density lipoprotein particles, swell into foam cells and release a cocktail of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. Vascular smooth muscle cells migrate and proliferate, stabilizing or destabilizing the growing plaque, and the resulting lesions can rupture catastrophically, triggering the clots that cause myocardial infarction and stroke. Every one of these steps, the authors emphasize, is a potential point of pharmacological or nutritional intervention.

Oxidative stress sits at the center of this cascade. Reactive oxygen species generated by dysfunctional endothelial cells, mitochondria and inflammatory enzymes promote the oxidation of LDL cholesterol, converting it into the oxidized LDL that macrophages find irresistible. Oxidative stress also inactivates nitric oxide, the endothelial gas molecule that keeps vessels dilated and inflammation suppressed. The body’s first-line antioxidant defenses, superoxide dismutase, catalase and glutathione peroxidase, normally hold these reactive species in check, and experimental work cited in the review shows that boosting these enzymes in mice inhibits smooth muscle proliferation and offsets pro-atherogenic gene expression in human endothelial cells. Yet the history of antioxidant therapy in cardiology is humbling: large randomized trials of vitamin E and C supplementation, including the ASAP study, the HOPE trial and the GISSI-Prevenzione trial, largely failed to reduce cardiovascular events. That failure is precisely why the field has shifted its attention to polyphenols, which act less like blunt radical scavengers and more like modulators of cellular signaling networks.

The review’s mechanistic core describes how specific polyphenols engage the master switches of vascular inflammation. Nuclear factor-kappa B, or NF-κB, is the transcription factor that switches on the genes for adhesion molecules and cytokines in endothelial cells and macrophages; the mitogen-activated protein kinase pathways feed into the same inflammatory program. Quercetin, for example, has been shown in macrophage models to disrupt the association between phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88, thereby dampening both MAPK/AP-1 and IKK/NF-κB-driven production of inflammatory mediators. On the protective side of the redox balance, polyphenols activate the Keap1-Nrf2 pathway, which induces the expression of endogenous antioxidant enzymes through the antioxidant response element. Anthocyanins, the pigments in berries, have been reported to activate Nrf2-ARE signaling as a modulator of redox homeostasis, while natural products broadly are increasingly recognized as activators of Nrf2 signaling with cardiovascular protective potential.

Resveratrol, the stilbene famous from red grapes, illustrates how deeply these compounds can reach into cellular metabolism. Structural studies reviewed by the authors show that resveratrol allosterically stimulates SIRT1, the NAD-dependent deacetylase linked to cellular stress resistance and longevity, and downstream effects extend to AMP-activated protein kinase, a central regulator of energy metabolism. In the context of cholesterol handling, resveratrol has been associated with improved cholesterol metabolism and with enhanced expression of the transporters ABCA1 and ABCG1, which export cholesterol from macrophage foam cells in the first step of reverse cholesterol transport. Catechins from green tea, particularly epigallocatechin gallate, and curcumin from turmeric each carry their own portfolio of anti-inflammatory, antioxidant and lipid-modulating actions documented across in vitro and animal studies. The picture that emerges is not one molecule, one target, but a network pharmacology in which dietary compounds nudge several atherogenic processes simultaneously.

What does the human evidence show? Clinical studies and meta-analyses reviewed by the authors suggest potential improvements in endothelial function, lipid profiles, blood pressure and inflammatory biomarkers after polyphenol-rich dietary interventions. Cocoa flavanols have produced some of the most consistent results: randomized trials, including the Flaviola Health Study, found that flavanol intake improved endothelial function and Framingham Risk Score in healthy adults, and a dose-response meta-analysis of randomized trials confirmed a relationship between cocoa flavanol intake and endothelial function. Olive oil polyphenols have their own track record: a randomized trial published in Annals of Internal Medicine showed that polyphenol-rich olive oil favorably modified heart disease risk factors, and later work found improvements in lipoprotein particle atherogenic ratios. In the PREDIMED trial substudy, higher polyphenol intake from a Mediterranean diet was associated with decreased inflammatory biomarkers related to atherosclerosis, and a crossover trial of hydroxytyrosol and punicalagin supplementation improved early markers of asymptomatic atherosclerosis in adults.

Yet the review is careful to flag the caveats, and they are substantial. Findings across clinical studies remain heterogeneous, and most of the supportive evidence rests on surrogate outcomes, such as flow-mediated dilation, oxidized LDL levels or C-reactive protein, rather than hard endpoints like myocardial infarction or cardiovascular death. Some trials are strikingly negative: a randomized placebo-controlled crossover trial found that resveratrol did not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects, even as a separate triple-blind trial reported that a grape extract containing resveratrol decreased oxidized LDL and apolipoprotein B in patients on primary prevention. Inter-individual variability looms large, since human studies show wide differences in how people metabolize and absorb polyphenolic compounds, driven by genetics, gut microbiota composition and dietary context. The authors conclude that clinical efficacy in atherosclerosis management remains uncertain and call for well-designed, long-term studies to clarify therapeutic relevance, optimal dosing and safety.

Two emerging strategies may help close the gap between promising mechanisms and clinical reality. The first is bioavailability engineering. Polyphenols are notoriously poorly absorbed, extensively metabolized and rapidly cleared, which limits the concentrations reaching arterial tissue. Nano-delivery systems, including liposomal and polymeric nanoparticle formulations, are being developed to protect these compounds through digestion and enhance their uptake; a recent randomized double-blind trial of a double-layered nano-liposomal curcumin formulation demonstrated enhanced bioavailability in humans, and pharmacokinetic studies of novel resveratrol formulations are following a similar path. The second strategy targets the gut microbiota, which transforms many parent polyphenols into metabolites that may actually be the biologically active species. Reviews of probiotic and phenolic approaches to atherosclerosis suggest that microbiota-targeted interventions could amplify cardioprotective effects, although the authors note that clinical efficacy for both nano-formulations and microbiota-directed approaches remains to be established.

Safety, too, deserves attention. Polyphenols are not automatically benign at high doses: they can interact with medicines, and reviews have catalogued possible side effects and drug interactions, while meta-analyses of curcumin and turmeric supplementation have examined effects on liver function with mixed findings. The review’s overall verdict is measured but constructive: antioxidants and dietary polyphenols may provide complementary approaches for cardiovascular risk reduction, best delivered through polyphenol-rich dietary patterns such as the Mediterranean diet rather than high-dose isolated supplements, and always alongside, not instead of, established therapies like statins and blood pressure control. For a disease that remains the leading cause of death worldwide, the message is that the chemistry of everyday plant foods is genuinely interesting at the molecular level, and that the next decade of long-term clinical trials will determine whether that molecular interest can be translated into fewer heart attacks and strokes.

Subject of Research: Molecular mechanisms by which dietary polyphenols influence atherosclerosis, endothelial dysfunction, oxidative stress and vascular inflammation

Article Title: Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation

Article References: Dey, A., Gautam, M. K., Modak, K., Dutta, P. P., & Mahajon, B. (2026). Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation. Molecular Biology Reports, 53(1), Article 1712. https://doi.org/10.1007/s11033-026-12914-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12914-4

Keywords: atherosclerosis, dietary polyphenols, endothelial dysfunction, oxidative stress, vascular inflammation, NF-kappaB, Nrf2, resveratrol, quercetin, curcumin, gut microbiota, cardiovascular disease

The researchers used a classic experimental strategy known as the pentylenetetrazol, or PTZ, kindling model. Kindling is a phenomenon in which repeated, subconvulsive stimulation of the brain progressively lowers the seizure threshold until full-blown seizures emerge spontaneously. It is widely regarded as one of the best laboratory approximations of how human temporal lobe epilepsy develops over months and years. In the study, thirty-two Wistar albino rats were divided into four groups. Two groups received PTZ at a dose of 35 milligrams per kilogram of body weight three days per week to induce kindling, while the control groups received equivalent volumes of saline. Half of the animals in each condition were also given resveratrol at 5 milligrams per kilogram per day by intraperitoneal injection for twenty-eight days. Twenty-four hours after the final injection, the team harvested brain tissue for a battery of molecular and histological analyses.

The behavioral and electrophysiological results were striking. Rats that received resveratrol alongside PTZ showed a dramatically longer delay before their first myoclonic jerk, the sudden muscle twitch that marks the earliest observable seizure manifestation, with the difference reaching a p-value of 0.0001. The treated animals also spent less time in the full seizure phase and displayed a markedly lower total spike count on electrocorticography, the technique of recording electrical activity directly from the surface of the brain. In practical terms, the polyphenol did not merely soften the symptoms of an already kindled brain; it slowed the kindling process itself, pushing back the point at which the animals’ neural circuits tipped into pathological synchrony.

Under the microscope, the protection was visible in the hippocampal CA1 region, a subfield of the hippocampus that is exquisitely vulnerable to seizure-driven damage and is a hallmark site of neuron loss in human epilepsy. Hematoxylin and eosin staining, the workhorse technique of histology that highlights cell nuclei and tissue architecture, revealed that PTZ-kindled rats suffered clear neuronal deterioration and inflammation in CA1. In the animals that also received resveratrol, tissue integrity was substantially preserved, with fewer signs of neuronal injury and a calmer inflammatory landscape. Because the hippocampus is central to memory formation as well as seizure generation, preserving its cellular architecture has implications that extend beyond seizure control to the cognitive decline that often accompanies chronic epilepsy.

To understand the mechanism, the team turned to sirtuin 1, or SIRT1, a NAD-dependent deacetylase enzyme that has become one of the most intensively studied stress-response regulators in biology. SIRT1 sits at the intersection of metabolism, inflammation, and cell survival, and resveratrol has long been described as one of its pharmacological activators. Immunofluorescence staining showed that PTZ kindling depleted SIRT1 levels in the hippocampus, consistent with the idea that repeated seizures overwhelm the brain’s endogenous protective machinery. Resveratrol treatment restored SIRT1 to near-normal levels, suggesting that the compound re-engages a cellular stress-response program that epilepsy had switched off.

At the same time, resveratrol suppressed the molecular signature of programmed cell death. Immunofluorescence revealed that PTZ elevated caspase-3, the central executioner enzyme of apoptosis, along with S100B, a protein released by glial cells that serves as a widely used biomarker of astrocyte activation and brain injury. Both markers fell significantly in the resveratrol-treated animals. Quantitative polymerase chain reaction confirmed the pattern at the transcript level: expression of caspase-3 and caspase-9, the initiator caspase that feeds into the executioner cascade, were both downregulated by resveratrol, while SIRT1 messenger RNA rose. Together, these data sketch a coherent pathway in which resveratrol activates SIRT1, and SIRT1 in turn restrains the apoptotic and glial responses that would otherwise dismantle hippocampal circuitry during epileptogenesis.

Perhaps the most novel finding concerns ion channels. The researchers measured the expression of three genes that directly govern the electrical behavior of neurons: SERCA2a, the sarco/endoplasmic reticulum calcium ATPase 2a, which pumps calcium back into intracellular stores and is essential for terminating calcium signals; CACNA1G, which encodes the alpha-1G subunit of T-type voltage-gated calcium channels, a channel family notorious for driving the rhythmic burst firing that underlies absence seizures and thalamocortical oscillations; and HCN2, a hyperpolarization-activated cyclic nucleotide-gated channel subunit that carries the current responsible for a neuron’s resting pacemaker activity. PTZ kindling disrupted the expression of all three. Resveratrol reversed those changes, significantly upregulating SERCA2a, CACNA1G, HCN2, and SIRT1 with p-values below 0.0001.

The significance of this ion channel result is hard to overstate. Intracellular calcium is the master currency of neuronal signaling, and its mishandling is a recurring theme in epilepsy, stroke, and neurodegenerative disease. Excess calcium triggers excitotoxicity, the process by which overstimulated neurons literally digest themselves, and it feeds forward into mitochondrial stress and apoptosis. By restoring SERCA2a, resveratrol appears to strengthen the cell’s ability to clear calcium from the cytoplasm, while the coordinated changes in CACNA1G and HCN2 suggest a recalibration of the channels that set neuronal firing thresholds. The authors describe this as the first in vivo evidence that resveratrol modulates these specific ion channel genes to control calcium balance and excitability during epileptogenesis, a claim that, if replicated, positions the polyphenol as something closer to a circuit-level neuromodulator than a generic antioxidant.

Several caveats deserve emphasis. The study was conducted in a rodent model with intraperitoneal dosing, and the dose used, 5 milligrams per kilogram per day, does not translate directly to human supplementation, particularly given resveratrol’s notoriously poor oral bioavailability. The kindling model captures certain features of acquired epilepsy but not others, and the paper reports results from a relatively small sample of thirty-two animals. The article was also shared early as an accepted, citable version subject to further editorial processing. None of this diminishes the internal consistency of the data, which align behavioral, electrophysiological, histological, protein-level, and transcript-level evidence around a single mechanistic story, but it does mean that clinical relevance remains a hypothesis rather than a conclusion.

Even so, the study lands at a moment of genuine unmet need. Roughly a third of people with epilepsy are resistant to existing antiseizure medications, which largely work by suppressing neuronal firing rather than by modifying the disease process itself. A compound that appears to act on epileptogenesis, the slow remodeling of brain circuits that turns a healthy brain into an epileptic one, rather than merely damping acute seizures, would represent a fundamentally different therapeutic strategy. Resveratrol’s safety profile in humans is comparatively well characterized, and its ability to cross the blood-brain barrier has been documented in prior work. The present findings do not justify self-treatment, and the authors themselves frame the work as mechanistic rather than clinical. But they do give researchers a concrete molecular target list, SIRT1, SERCA2a, CACNA1G, HCN2, and the caspase cascade, around which to design the next generation of neuroprotective experiments, whether those involve resveratrol itself, more potent SIRT1 activators, or drugs aimed directly at the calcium-handling machinery of the epileptic hippocampus.

Subject of Research: Neuroprotective effects of resveratrol on the hippocampus in a PTZ-kindling model of epilepsy

Article Title: The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy

Article References: Unal, O., Akgun-Unal, N., Tiryaki, E. S., Gulbahce-Mutlu, E., Simsek, S., & Dasdelen, D. (2026). The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05638-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05638-2

Keywords: resveratrol, epilepsy, hippocampus, SIRT1, PTZ kindling, ion channels, apoptosis, SERCA2a, CACNA1G, HCN2, neuroprotection, calcium signaling

Diabetic retinopathy is a devastating complication of diabetes, characterized by progressive damage to the microvascular network that nourishes the light-sensitive tissue at the back of the eye. For decades, clinicians have focused their attention on the blood vessels themselves, treating the leaky capillaries and abnormal new vessel growth with laser therapy, injections of anti-VEGF drugs, or surgery. But a growing body of evidence points to a quieter culprit: chronic neuroinflammation, driven in large part by microglia, the resident immune cells of the retina. When these cells become chronically activated in a high-glucose environment, they release a cocktail of pro-inflammatory cytokines that erode the structural and functional integrity of the retinal vasculature from the outside in.

The research team approached the problem with an unusually systematic strategy. Rather than testing piceatannol blindly, they combined network pharmacology with transcriptomic analysis to map the compound’s potential molecular targets against the gene signatures of diabetic retinopathy. The computational screen identified 159 overlapping targets shared between the polyphenol and the disease. Among these, one receptor rose to the top: C-C chemokine receptor type 5, or CCR5, a G protein-coupled receptor best known to immunologists for its role in directing immune cell traffic and, famously, as an entry co-receptor exploited by HIV.

Molecular docking studies predicted that piceatannol could bind directly to CCR5, and the researchers went on to validate that binding affinity experimentally. This mattered because the receptor’s ligand, the chemokine CCL5, was significantly upregulated in the diabetic retina. The picture that emerged was of a signaling cascade, CCL5 binding to CCR5 and triggering the pro-inflammatory transcription factor NF-κB, that could potentially be intercepted at its receptor by a dietary polyphenol. Single-cell and expression analyses added a crucial layer of specificity: CCR5 was found to be expressed predominantly in retinal microglia, placing the immune cells squarely at the center of the pathway.

To test the compound’s effects, the team built disease models at two scales. In the laboratory, they exposed microglia to high glucose concentrations to mimic the diabetic metabolic environment. In living animals, they induced diabetes in mice using streptozotocin, a chemical that destroys insulin-producing cells and produces sustained hyperglycemia. The results in the animals were striking. Mice treated with piceatannol showed restored retinal thickness, reduced formation of acellular capillaries, the ghost vessels that mark dead capillary segments in diabetic retinas, and attenuated vascular leakage, the pathological seepage of fluid and proteins that ultimately destroys vision.

The cellular mechanism behind these improvements centered on microglial polarization. Microglia, like their peripheral cousins the macrophages, can adopt broadly two functional states. The M1 phenotype is pro-inflammatory, unleashing tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6, along with inducible nitric oxide synthase, all of which batter neighboring tissue. The M2 phenotype is restorative, promoting tissue repair through markers such as arginase-1, interleukin-10 and transforming growth factor beta 1. In the diabetic retina, the balance tips decisively toward M1. Piceatannol treatment, the researchers found, inhibited microglial activation and M1 polarization, reduced the secretion of pro-inflammatory cytokines, and promoted the expression of M2-associated markers, all through modulation of the CCL5/CCR5/NF-κB signaling pathway.

The downstream consequences for blood vessels were equally telling. In vitro experiments using human retinal endothelial cells showed that when high glucose pushed co-cultured microglia into their inflammatory state, the endothelial cells suffered: the tight junction proteins zonula occludens-1 and Claudin-5, which zip adjacent endothelial cells together to form the inner blood-retinal barrier, were degraded. Piceatannol suppressed the high-glucose-induced M1 polarization of the microglia and, as a result, preserved the expression of these tight junction proteins. In other words, the compound’s vascular protection appears to be indirect, mediated through the immune cells rather than through a direct effect on the endothelium itself.

The team then put the CCR5 hypothesis to a rigorous causal test. Using small interfering RNA to knock down CCR5 expression, and separately employing pharmacological activation of the receptor, they confirmed that CCR5 sits at the center of the protective mechanism. When the receptor was silenced, piceatannol’s benefits were diminished or recapitulated by the knockdown itself; when the pathway was artificially activated, the compound’s protective effects were counteracted. This pattern of gain- and loss-of-function evidence strengthens the argument that the CCL5/CCR5/NF-κB axis is not merely correlated with the disease process but is functionally required for the drug’s action.

The significance of the work lies partly in its translational framing. Piceatannol is a naturally occurring stilbenoid, meaning it is already present in the human food supply and has been studied for anti-inflammatory and vascular-protective properties in other contexts. Demonstrating a concrete, mechanistically defined role in diabetic retinopathy raises the possibility of repurposing a well-characterized molecule for a condition that currently affects tens of millions of people worldwide. The network pharmacology approach also offers a template for how natural products with dozens of potential targets can be systematically triaged, using docking, transcriptomics and weighted gene co-expression network analysis to converge on the handful of targets that actually matter.

Substantial caveats remain before patients should expect a piceatannol-based therapy. The findings come from cell culture and streptozotocin-induced mouse models, which reproduce key features of diabetic retinopathy but do not capture the full complexity of human disease, which unfolds over decades of metabolic stress. Questions about bioavailability, dosing, retinal drug delivery and long-term safety in a diabetic population remain open, and the study was funded by Chinese national and municipal science programs without reported involvement of commercial drug development. Still, by pinpointing a druggable receptor on retinal microglia and showing that a food-derived polyphenol can restrain the inflammatory cascade that dismantles the blood-retinal barrier, the study adds a compelling new chapter to the growing recognition that diabetic blindness is as much an immunological disease as a vascular one.

Subject of Research: The role of piceatannol in modulating microglial polarization via the CCL5/CCR5/NF-κB axis to protect retinal endothelial cells in diabetic retinopathy

Article Title: Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis

Article References: Tu, Y., Guo, Y., Zhang, Y., Sun, H., Zhu, X., Shen, G., Gu, Y., Xie, L., Song, E., & Zhu, M. (2026). Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08893-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08893-6

Keywords: diabetic retinopathy, piceatannol, microglial polarization, CCR5, CCL5, NF-κB, retinal endothelial cells, blood-retinal barrier, neuroinflammation, tight junctions, network pharmacology, resveratrol

Synaptic plasticity is the biological substrate of learning and memory. At its core lies long-term potentiation, or LTP, a persistent strengthening of synaptic transmission that is widely studied in the hippocampus, the seahorse-shaped structure critical for forming new memories. The review situates resveratrol within the established molecular machinery of LTP: the activation of N-methyl-D-aspartate receptors, calcium influx, the recruitment of calcium/calmodulin-dependent protein kinase II, and the insertion and upregulation of AMPA receptors at the postsynaptic membrane. It also points to the signaling cascades that stabilize potentiated synapses, including the phosphoinositide 3-kinase/Akt pathway, the mammalian target of rapamycin, and the cyclic AMP response element binding protein, CREB, which drives the expression of plasticity-related genes. Disruption of any of these nodes, the authors note, can erode the synapse’s ability to encode experience.

One of the most consequential threats to that machinery is oxidative stress. The brain is exceptionally vulnerable to it: it consumes a disproportionate share of the body’s oxygen, is rich in lipids susceptible to peroxidation, and hosts neurons that are selectively sensitive to redox imbalance. When the production of reactive oxygen species outpaces the systems that eliminate them, the resulting damage can impair synaptic proteins, distort receptor signaling, and ultimately push neurons toward apoptosis, a programmed form of cell death that the body uses to maintain cellular equilibrium. The review emphasizes that reactive oxygen species are not simply toxic byproducts; at physiological levels they participate in the regulation of synaptic plasticity and memory, which means the therapeutic goal is restoration of balance rather than wholesale suppression of redox signaling.

Resveratrol enters this picture as a bidirectional modulator. According to the review, the compound can scavenge reactive oxygen species and blunt the damage inflicted by oxidative stress, thereby protecting the molecular substrates of plasticity. It also engages cellular defense systems more broadly, including the Nrf2 signaling pathway, which coordinates the transcription of antioxidant genes. In experimental models, resveratrol treatment has been shown to attenuate neuronal apoptosis after oxygen and glucose deprivation and reoxygenation by enhancing Nrf2 activation, and to protect embryonic neural stem cells from hydrogen peroxide-induced oxidative stress. These findings position the molecule as both a direct antioxidant and an indirect activator of the cell’s own protective programs.

The review gives particular attention to sirtuin 1, or SIRT1, a NAD-dependent deacetylase that resveratrol is known to activate and that has been implicated in synaptic health. In a model of developmental lead exposure, resveratrol reversed injury to hippocampal synaptic markers and countered SIRT1 inhibition, suggesting that the polyphenol can restore a key longevity-linked signaling axis in the brain. In neonatal mice with hypoxic-ischemic brain injury, resveratrol improved synaptic plasticity by alleviating neuroinflammation mediated through the SIRT1/NF-kappaB pathway. The authors also describe work showing that resveratrol upregulates AMPA receptor expression via AMP-activated protein kinase-mediated protein translation, a mechanism that directly increases the availability of the receptors responsible for fast excitatory transmission.

Beyond receptor-level effects, the review highlights resveratrol’s influence on brain-derived neurotrophic factor, BDNF, a growth factor central to the survival and maturation of dendritic spines, the tiny protrusions where excitatory synapses reside. It also examines adult hippocampal neurogenesis, the ongoing generation of new neurons in the dentate gyrus that evidence now supports in humans and that is increasingly recognized as a contributor to learning, memory, and mood regulation. Nutrition is one of the environmental factors known to shape this process, and the review frames resveratrol as a potential hippocampal plasticity enhancer capable of supporting both the birth of new neurons and the functional integration of existing circuits.

The translational implications extend across a striking range of disease models. In rats subjected to chronic cerebral hypoperfusion, resveratrol reversed deficits in synaptic plasticity and prevented cognitive impairment. In an Alzheimer’s-relevant model, it ameliorated spatial learning and memory impairment induced by amyloid-beta(1-42). In streptozotocin-induced diabetic rats, it improved cognitive performance by regulating both apoptosis and synaptic plasticity. The review further cites work showing that resveratrol modulates cocaine-induced inhibitory synaptic plasticity in dopamine neurons of the ventral tegmental area by inhibiting phosphodiesterases, and reports of antidepressant effects in an animal model of depression, underscoring that plasticity-related mechanisms cut across neurology and psychiatry alike.

Human evidence, though thinner, is provocative. A study of healthy older adults found that resveratrol supplementation improved memory performance and altered hippocampal functional connectivity alongside changes in glucose metabolism, hinting that the compound’s metabolic effects may underpin some of its cognitive benefits. Yet the review is candid about the obstacles. Resveratrol’s bioavailability is notoriously poor, with rapid metabolism limiting the concentrations that actually reach the brain. Dose is a critical variable: infinitesimal quantities appear beneficial for cell growth, while elevated doses can be detrimental to cell viability, a hormetic profile that complicates any simple recommendation. The literature also documents potential adverse effects, meaning that higher is emphatically not better.

The authors conclude that resveratrol’s ability to modulate signaling pathways governing cell survival, apoptosis, and synaptic plasticity gives it genuine potential to mitigate cognitive decline, particularly through enhancement of hippocampal plasticity and adult neurogenesis. But the path forward, they suggest, lies in resolving the dose-response paradox, improving delivery to the central nervous system, and validating the molecular mechanisms in rigorous clinical studies. For now, the compound remains a compelling research tool and a candidate therapeutic scaffold rather than a proven memory pill, a reminder that in neuroscience, as in the synapses themselves, the dose and the context determine everything.

Subject of Research: Resveratrol's modulation of synaptic plasticity and its therapeutic potential for cognitive decline

Article Title: Resveratrol as a modulator of synaptic plasticity: molecular mechanisms and future therapeutic perspectives

Article References: Zarifkar, A. H., & Safaei, S. (2026). Resveratrol as a modulator of synaptic plasticity: molecular mechanisms and future therapeutic perspectives. Molecular Biology Reports, 53(1), Article 1642. https://doi.org/10.1007/s11033-026-12836-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12836-1

Keywords: resveratrol, synaptic plasticity, hippocampus, oxidative stress, reactive oxygen species, long-term potentiation, SIRT1, BDNF, adult hippocampal neurogenesis, neuroprotection, CREB, NMDA receptor

The scientific leadership rests with Vicent Arbona Mengual of the Department of Biology, Biochemistry and Natural Sciences at Universitat Jaume I. His team also includes Miguel González Guzmán, coordinator of the GaMBiT research group – Genetic and Metabolic Integration of Biotic and Abiotic Interactions – together with Rosario Vidal and Beatriz Julián from the Institute of Advanced Materials (INAM-UJI). The wider consortium spans 11 partners from five countries: Spain, Italy, France, Germany and Sweden. Spanish participants include the Valencian Institute for Agricultural Research and the Galician University–Business Foundation. Italy contributes the Council for Agricultural Research and Economics (CREA) and UNITEC S.p.A., while France is represented by the French Agricultural Research Centre for International Development (CIRAD), the French National Research Institute for Agriculture, Food and Environment (INRAE) and Doriane SAS. Germany’s Computomics GmbH and CYBRES GmbH join the Swedish University of Agricultural Sciences to complete the partnership.

The project’s primary biological targets are sweet orange (Citrus sinensis) and mandarin (Citrus reticulata), two species that dominate global citrus production and consumption. The central objective is to generate genetically modified lines with greater resilience to the adverse conditions caused by climate change and its exacerbating effects on pests and diseases. Rising temperatures, altered rainfall patterns and shifting pest distributions are already straining citrus orchards across the Mediterranean and beyond, making the development of hardier varieties an increasingly urgent agricultural priority. By combining stress physiology expertise with advanced genetic engineering, the consortium aims to produce trees that can maintain productivity under conditions that would compromise conventional varieties.

Resilience is only half of the project’s ambition. CitrusAld also pursues the biofortification of citrus fruits to enhance their nutritional properties. Citrus fruits are widely regarded as functional foods that combine nutritional value with health-promoting properties, thanks to their antioxidant, anti-inflammatory and cardioprotective effects. The project seeks to increase naturally occurring beneficial compounds such as flavonoids and furanocoumarins, while also introducing a compound that citrus does not normally produce: resveratrol. This stilbene, best known as a constituent of grapes and cocoa, has been selected for its cardioprotective and anti-ageing properties. If successful, the work could transform an everyday fruit into an even richer source of bioactive molecules, blurring the line between conventional nutrition and functional food design.

Identifying which genes to modify in a genome as complex as citrus is a formidable challenge, and this is where artificial intelligence enters the project. The consortium will design and implement AI-based systems capable of analysing and integrating large volumes of biological data to pinpoint the most suitable target genes for each desired modification. Rather than relying on laborious trial-and-error approaches, the researchers intend to use computational pipelines that can sift through genomic, transcriptomic and metabolic datasets to prioritise candidate genes whose manipulation is most likely to yield stress tolerance or enhanced nutritional profiles. This data-driven gene discovery methodology represents one of the project’s key methodological innovations and reflects a broader trend of machine learning reshaping plant biotechnology.

Once target genes are identified, the actual genetic modifications will be carried out using New Genomic Techniques, or NGTs, which are now permitted in Europe under the newly updated regulatory framework. These techniques allow precise edits to a plant’s genome without introducing foreign DNA in the way older transgenic methods did, and their recent regulatory acceptance in the European Union has opened the door to projects of this kind. The consortium will also integrate novel materials capable of overcoming existing biological barriers that have historically limited the genetic efficiency of citrus species. Citrus is notoriously difficult to transform genetically, with recalcitrant tissues, long generation times and barriers to regeneration, so the development of new delivery materials could prove as consequential as the gene edits themselves.

In parallel with genome editing, the consortium will explore complementary strategies based on RNA interference technology. RNAi allows researchers to slow down or silence the expression of specific genes without permanently altering the genome, offering a reversible and highly targeted means of modulating plant traits. A central technical hurdle for RNAi in plants is delivering the interfering molecules into plant tissues, where cell walls and other barriers block conventional approaches. The CitrusAld team plans to use novel materials as delivery vehicles into plant tissues, an approach that draws on the materials science expertise within the consortium and could establish new protocols for transient gene silencing in woody perennial crops.

The funding mechanism behind the project is as distinctive as its science. The EIC Pathfinder Challenges programme, part of the European Innovation Council, supports highly innovative, high-risk scientific research with the potential to generate entirely new technologies in the future. It deliberately funds the early stages of research, when ideas are still being explored in the laboratory and there is not yet a clear commercial application. The programme’s objective is to establish the scientific and technological foundations for breakthroughs that, in the long term, can transform entire sectors or help address major societal challenges. For a crop that underpins the economies of Mediterranean regions and provides vitamin-rich food to billions of people, the societal stakes of climate-resilient citrus are considerable.

The four-year project will begin in October 2026 under proposal number 101306995, giving the consortium a defined window in which to deliver its gene discovery pipelines, transformation protocols and biofortified citrus lines. The breadth of the partnership – spanning academic plant science institutes, agricultural research organisations, materials specialists and companies – suggests a deliberate effort to cover the full pipeline from fundamental gene discovery to applied field-relevant varieties. The involvement of computational firms such as Computomics and CYBRES alongside plant science heavyweights like INRAE and CIRAD signals that the AI and data integration components are treated as core infrastructure rather than an afterthought.

For consumers and growers alike, the project’s promise is twofold: citrus trees better equipped to endure a warming, pest-pressured world, and fruit with an enhanced portfolio of health-promoting compounds. Whether engineered resilience and resveratrol-enriched oranges will reach commercial orchards remains a question for the years beyond the project’s horizon, but CitrusAld represents one of the most comprehensive European attempts to marry genomics, artificial intelligence, materials science and plant breeding in service of a single iconic crop. As climate change accelerates and the tools of biotechnology mature, the humble orange may become a showcase for how 21st-century science re-engineers the foods we have cultivated for millennia.

Subject of Research: Genetic modification of citrus crops for climate resilience and nutritional biofortification

Article Title: Universitat Jaume I leads European consortium to develop genetically modified citrus lines with greater resilience to climate change, pests and diseases

Article References: Universitat Jaume I leads European consortium to develop genetically modified citrus lines with greater resilience to climate change, pests and diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: citrus, genetic modification, climate change, EIC Pathfinder, Universitat Jaume I, New Genomic Techniques, RNA interference, biofortification, resveratrol, artificial intelligence, sweet orange, mandarin

TGF-β sits at the heart of the body’s wound-healing machinery, and ionizing radiation hijacks that machinery in a destructive way. When tissue is irradiated, reactive oxygen species are generated that can directly activate latent TGF-β stored in the extracellular matrix, converting the inactive precursor into its potent signaling form. Decades of experimental work, including studies in irradiated murine mammary gland and lung, have shown that TGF-β levels rise in a dose-dependent fashion after thoracic irradiation and correlate with the later development of pulmonary fibrosis. Once activated, the cytokine binds to cell-surface receptors and triggers the phosphorylation of Smad2 and Smad3 proteins, which then translocate into the nucleus to reprogram gene expression toward collagen production, matrix remodeling, and inflammatory signaling.

The pathological consequences of this cascade are well characterized. TGF-β drives the transition of resident fibroblasts into myofibroblasts, the contractile cells that churn out excessive extracellular matrix and deposit collagen throughout the injured tissue. It also promotes epithelial-mesenchymal transition, a process in which epithelial cells lose their normal identity and acquire invasive, matrix-producing characteristics, further amplifying the fibrotic response. In addition, the pathway engages non-canonical branches, including the MAPK and PI3K/Akt cascades, which cross-talk with the Smad system and reinforce inflammation, cell survival, and matrix deposition. Because TGF-β is also implicated in tumor progression and immunosuppression, modulating this axis is a delicate balancing act for any therapeutic strategy aimed at protecting normal tissue during cancer treatment.

Enter the phytochemicals. The review, led by Pouya Goleij and colleagues with contributions from researchers across Iran, the United States, Saudi Arabia, and South Korea, surveys a diverse group of plant-derived molecules with reported multi-target effects on TGF-β signaling. The roster includes curcumin from turmeric, resveratrol from grapes, epigallocatechin gallate (EGCG) from green tea, quercetin from many fruits and vegetables, berberine from barberry, honokiol from magnolia bark, and silibinin from milk thistle. Each of these compounds has been studied extensively in preclinical models of fibrosis, and each appears to converge, by one route or another, on the TGF-β axis.

The mechanistic details vary by compound but share recurring themes. Curcumin has been shown to inhibit Smad signaling in kidney epithelial cells, to downregulate the TGF-β/Smad2/3 pathway in thyroid carcinoma cells, and to block the differentiation of lung fibroblasts into myofibroblasts, in part through activation of the nuclear receptor PPARγ. EGCG appears to interact directly with the TGF-β type II receptor, suppressing signaling at the receptor level, and has been reported to block TGF-β1/Smad-driven epithelial-mesenchymal transition in cancer cells. Quercetin suppresses TGF-β/Smad signaling in keloid-derived fibroblasts and blocks the TGF-β1/PI3K/AKT pathway in models of peritoneal adhesions. Berberine engages the TGF-β receptor itself and attenuates fibrosis through AMPK-mediated inhibition of TGF-β1/Smad signaling. Honokiol and silibinin likewise dampen Smad2/3 phosphorylation and reduce matrix protein expression in lung, renal, and skin fibrosis models.

What makes these findings particularly relevant to radiotherapy is that several of the compounds have now been tested in radiation-specific settings, not merely in chemically induced fibrosis. Curcumin attenuated radiation-induced inflammation and fibrosis in rat lungs, and liposomal curcumin inhibited radiation pneumonitis while sensitizing lung tumors to radiation, an encouraging combination of normal tissue protection and tumor control. Quercetin inhibited radiation-induced skin fibrosis in animal models and, delivered in liposomes, protected against radiation-induced pulmonary injury. EGCG inhibited irradiation-induced pulmonary fibrosis in adult rats and protected intestinal epithelial cells from ionizing radiation in vitro and in vivo. Resveratrol, combined with alpha-lipoic acid, mitigated radiation-induced pneumonitis and lung fibrosis in experimental studies. Berberine has been evaluated for radiation-induced skin injury using proteomic and network pharmacology approaches, and silibinin protected normal lung tissue against radiation injury without reducing the therapeutic efficacy of radiotherapy against lung cancer in preclinical work.

The review is careful to flag a major caveat: most of the mechanistic evidence for these compounds derives from non-radiation fibrosis models, such as those induced by bleomycin, carbon tetrachloride, or silica. While those models share downstream fibrotic pathways with radiation injury, the initiating events differ, and the redox-driven activation of latent TGF-β that is characteristic of irradiated tissue may not be fully recapitulated. Direct validation in radiation-specific models is therefore essential before the preclinical promise can be considered firmly established. The authors also note complexity in the biology itself, as resveratrol has been reported to exert dose-dependent anti-fibrotic or even pro-fibrotic effects in the kidney, a reminder that phytochemicals are not uniformly protective and that dose, context, and tissue type all matter.

Early clinical signals exist but remain preliminary. A randomized, double-blind, placebo-controlled trial of curcumin in thirty breast cancer patients reported reduced severity of radiation dermatitis, and a pilot trial suggested radioprotective effects of curcumin supplementation in prostate cancer patients. Oral nanomicelle curcumin was evaluated for preventing radiotherapy-induced mucositis in head and neck cancer patients, and a combination antioxidant formulation including resveratrol showed protective effects against skin toxicity in breast radiotherapy. EGCG has been tested in a prospective three-arm randomized trial for preventing radiation-induced esophagitis in lung cancer patients and in a phase 2 double-blind, placebo-controlled trial for preventing dermatitis in breast cancer patients receiving postoperative radiotherapy. These studies are mostly small-scale and, in some cases, uncontrolled, and the review emphasizes that their findings require confirmation in larger, adequately powered, well-designed clinical trials before any firm claims of benefit can be made.

Several outstanding questions will shape the field’s next steps. The most critical concern is whether dampening TGF-β signaling in patients undergoing radiotherapy might inadvertently compromise tumor control, given the pathway’s established roles in cancer progression, immune evasion, and resistance to therapy; silibinin’s preclinical profile, which protected normal lung without reducing therapeutic efficacy, offers a template for the kind of evidence that will be needed. Pharmacokinetics pose another hurdle, as compounds like curcumin and resveratrol have notoriously low bioavailability, which has driven interest in nano-enabled and liposomal delivery systems, such as the nano-formulated EGCG that ameliorated silica-induced pulmonary fibrosis in rats. Safety in patients with impaired organ function, the possibility of paradoxical pro-fibrotic effects at certain doses, and the challenge of timing interventions relative to the course of radiotherapy all remain open. Still, the convergence of mechanistic plausibility, multi-target preclinical activity, and early human signals positions these plant-derived molecules as credible candidates for supportive strategies against radiation-induced normal tissue injury, pending the rigorous clinical validation that the review’s authors rightly demand.

Subject of Research: Phytochemical modulation of TGF-β signaling in radiation-induced fibrosis

Article Title: Phytochemicals modulating TGF-β signaling in radiation-induced fibrosis

Article References: Goleij, P., Mirzaei, M., Babamohamadi, M., Sadreddini, S., Abolfazli, S., Tabari, M. A. K., Movafagh, A., Aschner, M., & Khan, H. (2026). Phytochemicals modulating TGF-β signaling in radiation-induced fibrosis. Molecular Biology Reports, 53(1), Article 1653. https://doi.org/10.1007/s11033-026-12867-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12867-8

Keywords: TGF-β signaling, radiation-induced fibrosis, phytochemicals, curcumin, resveratrol, EGCG, quercetin, berberine, Smad pathway, radiotherapy, fibrosis, radioprotection